Nicolai Haugsted
Novo Nordisk and Eli Lilly are currently experiencing a massive increase in interests regarding their two new weight-loss drugs – but which one is actually most effective?
Novo Nordisk and Eli Lilly are no longer just competing for market share — they are battling over which obesity treatment actually delivers the strongest medical results.
That was a central theme in a recent episode from the YouTube channel Investeringspodcasten, where the discussion shifted away from stock prices and focused instead on the effectiveness of the drugs themselves.
Eli Lilly gaining momentum medically
According to the discussion, Eli Lilly’s treatments are increasingly being viewed as the strongest performers when it comes to weight loss results.
Particular attention was placed on Mounjaro and Zepbound, which several studies have shown can produce greater average weight reduction than Novo Nordisk’s Wegovy.
Participants in the podcast highlighted that the medical conversation has changed noticeably over the past year. Earlier, Novo Nordisk was widely seen as the unquestioned leader in obesity medicine through Wegovy and Ozempic.
Now, Eli Lilly is increasingly being described as the company pushing the field forward scientifically.
Weight loss numbers draw attention
Much of the debate centers on how much weight patients actually lose during treatment.
Eli Lilly’s drugs target two hormones instead of one, something many experts believe may explain the stronger results seen in several clinical trials.
Novo Nordisk’s medicines mainly focus on GLP-1 receptors, while Eli Lilly combines GLP-1 with GIP activity — a combination that researchers and doctors are watching closely.
Discussion on Investeringspodcasten suggested that many physicians are beginning to see Lilly’s treatments as potentially more effective for a broader group of obesity patients.
Pill race could change everything
Focus also turned toward the next major battleground: obesity pills.
Both pharmaceutical giants are developing tablet-based treatments designed to replace or complement injections.
Participants in the video stressed that oral medication could dramatically change the market because many patients remain hesitant about injections.
Medical effectiveness will likely decide the winner there as well. Questions about side effects, muscle loss, long-term sustainability and patient adherence were all mentioned as critical factors in determining which company ultimately produces the superior treatment.
Novo still holds major strengths
Despite Eli Lilly’s growing momentum, the discussion did not portray Novo Nordisk as falling behind completely.
Novo was repeatedly described as the company that transformed obesity medicine into a global mainstream treatment in the first place.
Wegovy and Ozempic still remain among the most recognized obesity and diabetes drugs worldwide, and participants noted that Novo continues working aggressively on newer generations of treatments.
Conversation throughout the podcast ultimately circled around a medical question now dominating the obesity field: not who sells the most medicine — but whose treatment actually works best for patients.
